Patient and Clinician. Connected.

Investor presentation February 2025







Patient and Clinician. Connected.



Grasp Investor Presentation ≡ At a glance Technology Products Investment

Grasp

# At a glance

#### Grasp at a glance

Digital Health Tech firm connecting clients and clinicians through innovative technology.

Our solutions are developed in partnership with ultimate clients and leading health professionals

Hours invested in technological solution

25 000

Countries with patents registered

16

Products launched

Products in pipeline

Focus areas

Real-time tracking of patient data

Remote monitoring and treatment

Al-driven health treatment

#### Selected partners

















MAJOR MILESTONES

#### **Partners**







#### Pilot Helse

Grasp awarded Pilot Health framework worth NOK 35 million. Project period 2022 – 2025

- Research and develop remote patient monitoring solution, focusing on post operative treatment
- Research and develop live symptom assessment solution for adults and children, focusing on dental treatment

Dental clinics in Norway

UiB Odontologen

#### Grasp Aware for dentists

Grasp Aware launched in November 2023

- Implement real-time communication solution for patients and dentists, facilitating immediate feedback and comfort adjustment
- Commercialize live symptom assessment solution for adults and children

Concentra Al


#### Grasp post operative AI in USA

Agreement with Concentra AI on using Grasp Device in combination with AI software

- Partner with Concentra AI to leverage analytics for personalized patient care and improve post operative outcomes
- Integrate Al' with Grasp's hardware for more accurate and efficient post-operative monitoring, aiming to reduce recovery times and complications

#### Why invest in Grasp

# Well-positioned to capture attractive opportunities in the fast-growing digital health market.



 $\equiv$ 

#### Our team

#### Experienced and multi-disciplined team

Team fast facts (excl. BoD)

 $\rightarrow$ 

Average years of professional experience per team member



#### Group management & Business development



Tormod G. Opdal Chief **Executive Officer** 

Allan Junae

Hvldal

Operatina Officer



Per Øvstein **Opdal Chief Medical** Officer MD



Paweł Błachut Hardware Lead

#### **Board of Directors**



Stener **Kvinnsland** Chairman





Gunnar Amundsen Board member



#### Collaborative partners



**Richard Watson** Consultant Concentra Al. USA



**Dan Stoller Reaulatory Consultant Cenit Consultina** 



Tomasz Brzozowski Software Lead



Lars Henrik Østevold Board member



Jøraen A. Nilsen Board member

Janiche

B. Heltne

member

Torbiørn


Gielsvik

member


Board

Board

 $\equiv$ 



#### Grasp Exceptional people





#### Introducing Grasp.

Capturing subjective patient data



In real time









FDA

Registered, Class II

**MDR** 

Approved, Class I



Charged by USB



iOS / Android




Bluetooth




Days battery life in standby mode 

# Technology


#### Grasp transforms patient experiences into actionable treatment insights





# The Grasp ecosystem consists of multiple interfaces and applications, making it a flexible and powerful tool for all stakeholders













### Intellectual property protections



#### **Existing protections:**

- The Grasp Device is CE marked and Medical Device Approved in the EU
- FDA medical device registration for the Grasp Device in USA
- FDA medical device registration for the Grasp Aware in USA
- The Grasp Device is patent protected and validated in 16 European countries
- The Grasp Device is design patented in Norway and EU
- Grasp is trademark registered in Norway and EU




#### **Planned protections:**

- Trademark registration for Grasp Aware in USA (2025)
- Design patent in for Grasp Device US (2025)
- FDA medical device certification for the Concentra Al software in USA (2025)

#### •

#### **Risk Management**







**Financial** 



Sustainability



Reputation



**Product** 


#### Our tools for exercising risk management are:

- Clear definition of roles and responsibilities
- Risk management activities are integrated in processes
- Common methods, tools and decision criteria
- Arenas and systems for assessment, communication and reporting of risk in the company

### Our approach to risk management is based on the following standards:

- ISO 14971 Medical devices Application of risk management to medical devices
- ISO 13485 Medical devices QMS Requirements for regulatory purposes
- ISO 27001 Information security management
- ISO 31000 Risk Management
- Normen: The code of conduct for Information Security and privacy in the health and care sector


# Journey towards fully automated Al driven treatment Revolutionizing healthcare delivery




# Products

18

#### Products & Market Opportunities





Launched Q4.2023

#### Grasp Aware

Real-time monitoring and communication solution

#### Connecting patient and dentist

Control and communication are core values when visiting the dentist. We can all relate to the difficulty of communicating and the lack of control during dental treatment. For some patients, this leads to avoiding visits to the dentist.

Grasp connects patients and dentists, provides safe and effective care, and ultimately increases patient compliance over time.

Norwegians afraid of going to the dentist, and do so less often than they should \*

**1** (1/5 person)

Norwegians not going to dentist at all due to fear or anxiety \*

250k

\* Norsk tannhelseforsikring

#### Business case

- Simplified regulation: A less complex regulatory environment speeds up market entry.
- **Market potential:** A transparent market dominated by private practices with a high willingness to pay.
- Clear value demonstration: Ease of proving value through measurable improvements in patient care.
- **Expansion platform:** Early successes in dentistry establish credibility for scaling into broader healthcare markets.



• 0

Grasp Aware

Launched Q4.2023


## Grasp Aware How does it work?

1




The dentist gives the Grasp device to the patient to hold during treatment. By squeezing it, patients can easily communicate with the dentist.

3



A firm squeeze and hold triggers a stop signal, notifying the dentist through a change in sound and visual feedback. The dentist will then pause to assess the patient's condition.

2



By squeezing the Grasp, patients trigger auditory and visual feedback that communicates to their dentist that they are doing fine.

4



After the treatment, the patient will receive a report that enhances their understanding and equips them for better self-care.




Launched November 2023

#### **Grasp Aware**

#### Business plan and sales projections





#### Segments

#### Private

Large and medium dental clinic chains

#### **Public**

Clinics for patients who have trauma from torture, abuse, or diagnosed with odontophobia (TOO). There are around 40 clinics dedicated to TOO in Norway.

#### Projected number of new solutions sold 2024-2027

Number of solutions	2024	2025	2026	2027
Norway	100	300	400	500
Sweden/Denmark		70	300	300
USA		50	750	2 750
Total	100	420	1450	3 550



Launched November 2023


#### **Grasp Aware**

#### Sales traction and projection for 2024

220




#### Current deployed solutions and short-term projection



Launched November 2023

#### Grasp Aware Some of our valuable customers







Launched November 2023

#### **Grasp Aware** Market timeline

Q4.2023

Version 1.0

Grasp Aware

Q1.2024

Market

introduction in

Norway

Q2.2024

Market

introduction in

Norway

Q3.2024

Research Grasp

Aware for children

Q4.2024

Distribution

agreement in

Norway

Q1.2025

Publication of research

Q2.2025

Scaling in Norway

Market Introduction Plan

for USA

Launch Sweden and Denmark

Norway

Dental Module Piloted and Finalized

25 solutions deployed

> Focus on quality and customer feedback

50 solutions deployed

Focus on customer success 60 solutions deployed

> Focus on upselling

80 solutions deployed

Focus on research and resources in sales

100 solutions deployed

Focus on distributors and dental chains

150 solutions deployed

Focus on public customers 300 solutions deployed

400 solutions deployed

Focus on Sweden and Denmark

**USA** 


Grasp Device registered as FDA Class II medical device

Grasp Aware registered as FDA Class II medical device

Screen and contact potential pilot partners and distributors

Pilots at selected clinics and attend to fares

Funding secured



Technology

Remote Patient Monitorina

26

In development

#### Remote Patient Monitoring

#### Post-Operative Settings: Joint replacement surgeries

Project Overview	
Segment	Patient/Provider Solution for Orthopedic Post-Operative Communication
Customer	Hospitals, Ambulatory Surgery Centers
Geography	North America
Grasp OS	Partnership with Concentra Al
Grasp role	Co-owner, Hardware vendor
Status	Development, piloting, preparing for launch - 2025

#### About the product

A communication tool for doctors and patients that supplies

#### For patients:

- A general source of information about the post op period
- Guidance on signs that may indicate the need to return to the hospital/ED
- A constant communication with their provider

#### For providers:

- A real time window into the patient's post op condition
- Metrics to focus on the patient's recovery journey
- Communication channels that integrate with the patient's tools

#### Value proposition

My Connect Post-Op is a hardware + software solution that leverages a clinically conversant AI to enable providers to identify patient needs and take action during intervention windows prior to re-admittance.

- Real-time symptom tracking on-the-go with the portable Grasp device.
- Simplified patient and clinician communication via a specialized conversational Large Language Model interface.
- Personalized care through Al-powered analysis and treatment insights.

#### Team



Per Øystein Opdal Product Manager Grasp



Research team Pilot Helse Haukeland University Hospital



Richard

Watson

Concentra Al



Software **Development Team** USA

#### Objectives 2024

- Conduct feasibility study at Kysthospitalet Hagavik (started Nov. 2023)
- Manufacture and deliver 1 000 Grasp devices for use in 4 clinical trials
- Conduct clinical trial in Norway in collaboration with Haukeland University Hospital and Concentra Al
- Plan and conduct three clinical trials in USA in collaboration with Concentra Al

Remote Patient Monitoring

In development

#### Remote Patient Monitoring


#### How does it work?

1



Following a joint replacement surgery, our patient begins the recovery under hospital care.

3



At home, our patient manages recovery with Grasp, tracking pain levels and providing health updates effortlessly, ensuring peace of mind in real-time.

2



Before discharge, our patient receives the Grasp device, equipped with guidance for tracking symptoms, ensuring a continuum of care beyond the hospital walls.

4



Software analytics engine processes health data in real-time, equipping providers with actionable insights to tailor post-operative care for each patient's unique journey.

**Grasp Investor Presentation** 

 $\equiv$ 

At a glance

Technology

Products


Investment

• 0

Remote Patient Monitoring


In development

## My Connect Post-Op How does it work?



# Investment

#### Timeline





#### Traction

Strategic shift from development to commercial traction Pilots conducted

Pilot users

**Events** captured

Patients treated using Grasp Aware

**Grasp Aware customers** 

13

6

400 000

600

**42** 

#### Selected partners




























#### Value proposition and growth trajectory



#### 

#### Objectives and investment highlights

Objectives

Q4 2024 - Q1 2026

**Grasp Aware** 

Sell 1000 Grasp Aware solutions to dental clinics **Grasp Aware** 

Research publication Grasp Aware for children in collaboration with UiB **Grasp Aware** 

Plan and financing for introduction of Grasp Aware in USA RPM

Manufacture and deliver 1000 Grasp devices to Concentra Al RPM

Clinical trial of Grasp and AI in post operative setting

We are currently raising equity and loan funding

Equity capital, Investors

10 m

Loan funding, Innovation Norway

3.9m

Securing runway until

Q1 2026



#### Multiple application areas and market opportunities

Opportunity	Situation	Key drivers
Grasp Aware  Real-time monitoring and communication solution for dental clinics	<ul> <li>Launched in Q4 2023</li> <li>62 Grasp Aware solutions rolled out to 42 unique dental clinics</li> <li>Back log of clinics that want to test and adopt the solution</li> </ul>	Sales to new clinics in Norway Sales to new clinics in USA (2026) Upselling to existing clinics  Market  5 000 dentists in Norway 200 000 dentists in USA
Remote Patient Monitoring Partnership with Concentra Al	<ul> <li>Partnership agreement signed with Concentra AI in March 2024</li> <li>Grasp to deliver 1 000 Grasp devices for use in US pilots</li> <li>Grasp compensated 10% stock ownership in Concentra AI</li> <li>Concentra AI in process with FDA, Q3 2024</li> </ul>	Stock appreciation Strategic collaboration with FDA approved AI Software Sale of Grasp devices  Market  1.25 million joint replacement surgeries in USA annually
R&D: Future applications  Chronic and preventive care Telehealth Mental health Elderly care Pediatric care Clinical research	<ul> <li>Grasp device CE-marked, patented and regulated as class 1 medical device in EU (MDR) and North America (FDA)</li> <li>Flexible software platform that easily can be tailored new medical indications</li> <li>Conducted 13 pilots on various indications</li> </ul>	<ul> <li>Technological innovations</li> <li>New products</li> <li>Proof of product effectiveness through clinical trials</li> <li>Higher medical device classification</li> </ul>

Grasp Investor Presentation  $\equiv$  At a glance Technology Products Investment



35

116 shareholders

Total shares 101 735


Granted options 11 502

Founders / Board owns 51,4 %

Health investors and founders own 65%

Dentists own 6,5%

#### Ownership per Investor Group



Shareholder	Shares	Ownership
Grasp Eiecompagnie AS	30 000	29.5%
Futurum Utvikling AS	13 741	13.5%
Chambers Bay AS	9 459	9.3%
Hauge Medtech Invest AS	5 217	5.1%
Maximum Holding AS	4 631	4.6%
Prosjektkonsult AS	3 873	3.8%
Dentalmed AS	3 125	3.2%
P H Opdal AS	2 622	2.6%
Örn AS	2 326	2.3%
Gil Invest AS	1649	1.6%
Subtotal top 10 shareholders	76 733	75.4%
Other shareholders (94 shareholders)	25 002	24.6%
Total all shareholders	101 735	100%



Patient and Clinician. Connected.

Investor presentation February 2025

Thank you!



